Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd ( (AU:IMM) ) just unveiled an update.
Immutep Limited has requested and been granted a trading halt on its ordinary shares on the ASX, effective 6 March 2026, pending the release of an announcement. The halt is intended to prevent trading on an uninformed basis while the company prepares to disclose the results of a pre-specified interim futility analysis for its Phase III TACTI-004 (KEYNOTE-F91) trial of lead candidate Eftilagimod Alfa.
The trading halt will remain in place until either the outcome of the futility analysis is announced or normal trading resumes on 11 March 2026, whichever occurs first. The move underscores the potential significance of the interim data readout for Immutep’s late-stage clinical program and may have important implications for investor sentiment, the future development of Eftilagimod Alfa, and the company’s positioning in the competitive immuno-oncology market.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is an Australian biotechnology company focused on developing immuno-oncology therapies. Its lead product candidate is Eftilagimod Alfa, which is being evaluated in advanced clinical trials, including the Phase III TACTI-004 (KEYNOTE-F91) study, positioning the company within the cancer immunotherapy space.
Average Trading Volume: 3,938,761
Technical Sentiment Signal: Buy
Current Market Cap: A$545.3M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.